- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT02491177
Mother and Infant Visit Adherence and Treatment Engagement Study (MOTIVATE!)
22 kwietnia 2021 zaktualizowane przez: University of Colorado, Denver
Maximizing Adherence and Retention for Women and Infants in the Context of Option B+
This is a 2x2 factorial cluster randomized trial of two interventions to improve retention and adherence for women and infants on Option B+.
The overall goal is to determine which intervention (or combination of interventions) maximizes antiretroviral therapy (ART) adherence and retention in care in the context of Option B+ and thus improves maternal and infant health outcomes.The proposed study will be conducted in rural Nyanza Province, Kenya at 20 low-resource primary health care facilities and associated communities supported by Family AIDS Care and Education Services (FACES), a President's Emergency Plan for AIDS Relief (PEPFAR)-funded HIV prevention care, and treatment program, ((AIDS) acquired immune deficiency syndrome, (HIV) human immunodeficiency virus) .
The investigators will assess both process and outcome indicators using a 2x2 factorial design, in which equal numbers of clusters will be randomized to one of the interventions (community-based mentor mothers or theory-based mobile text messages), both interventions, or standard of care.
The interventions will be added to fully integrated high quality HIV and antenatal, maternal, neonatal, and child health (ANC/MNCH) services already offered at these sites.
Przegląd badań
Status
Zakończony
Interwencja / Leczenie
Szczegółowy opis
In order to eliminate new pediatric HIV infections, save maternal lives, and simplify antiretroviral therapy (ART) implementation in settings with generalized HIV epidemics, current World Health Organization (WHO) guidance recommends lifelong triple ART for all pregnant and breastfeeding women (Option B+).
However, despite the promise of Option B+ to remove logistical barriers and to promote maternal health through life-long ART, this strategy brings challenges.
Key amongst these challenges are adherence to ART and continuous retention in HIV care, especially for women who do not require ART for their own health.
Barriers to adherence and retention in care for prevention of mother-to-child transmission (PMTCT) have been identified at the individual, interpersonal, community, and health facility levels; yet specific barriers in the context of Option B+ are not well understood.
The investigators' study will be conducted at 20 health facilities and associated communities in Nyanza Province, Kenya where Mother to Child Transmission (MTCT) rates prior to Option B+ roll-out remained near 10%, despite the wide availability of PMTCT services.
As Option B+ is scaled up in Kenya, it is essential to identify effective methods to ensure long-term adherence and retention in care for mother-baby pairs, throughout pregnancy, breastfeeding, and beyond.
Building on the investigating team's prior research experience in this setting, the investigators propose to gain understanding of and address potential barriers at the individual, community, and health facility levels through formative research with HIV-positive pregnant and postpartum women, their male partners, and health care providers.
This information will be used to refine two proposed interventions that are highly likely to maximize ART adherence and retention in care among HIV-infected pregnant women and HIV-exposed infants.
These interventions will be rigorously tested in rural Kenya, using a cluster randomized 2x2 factorial design.
The evidence-based interventions to be tested will include 1) community Mentor Mothers (cMM) who will provide support for ART adherence and retention in care for HIV-positive women in the community and 2) individually tailored, theory based mobile phone text messages to help retain women and infants in HIV care.
The investigators' overall goal is to determine which intervention (or combination of interventions) maximizes ART adherence and retention in care in the context of Option B+ and thus improves maternal and infant health outcomes.
The investigators' primary outcomes will include ART adherence at 12 months postpartum and retention in care, measured by a documented HIV care visit within 90 days prior to 12 months postpartum.
Secondary outcomes will include MTCT at 6 weeks, 12 months and 18 months; as well as maternal viral loads and CD4 counts.
Results from this study will inform the scale-up of Option B+ in Kenya by identifying effective interventions and combinations of interventions that can reduce barriers and increase facilitators of optimal ART adherence and retention in care with the aims of reaching the elimination of mother to child transmission of HIV and significantly improving maternal health.
Typ studiów
Interwencyjne
Zapisy (Rzeczywisty)
1338
Faza
- Nie dotyczy
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Lokalizacje studiów
-
-
-
Nairobi, Kenia
- Kenya Medical Research Institute
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
18 lat i starsze (Dorosły, Starszy dorosły)
Akceptuje zdrowych ochotników
Nie
Płeć kwalifikująca się do nauki
Kobieta
Opis
Inclusion Criteria:
- Age 18 years or older,
- HIV-infected pregnant women and their HIV-exposed infants pairs,
- attends the antenatal care (ANC) clinic at one of the study sites.
Exclusion Criteria:
- Less than 18 years of age,
- HIV-infected women not currently pregnant,
- not HIV-infected at the time of the first ANC visit.
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Zapobieganie
- Przydział: Randomizowane
- Model interwencyjny: Przypisanie czynnikowe
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Inny: cMM and Text Messaging
Participants randomized to this arm will receive both the community mentor mother and mobile phone text messaging intervention.
The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits.
The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
|
Home visits from community mentor mothers
Text messages received on mobile phone
|
|
Inny: cMM Only
Participants randomized to this arm will receive the community mentor mother intervention only.The community mentor mother intervention will consist of home visits conducted by the community mentor mother who will assist with safe disclosure, support safe infant feeding, promote safer sex and family planning, encourage early infant testing and follow up, and promote ART adherence and return for HIV care visits.
|
Home visits from community mentor mothers
|
|
Inny: Text Messaging Only
Participants randomized to this arm will receive the mobile phone text messaging intervention only.
The text messaging intervention will entail participants receiving tailored mobile phone text messages at their preferred frequency and in their preferred language.
|
Text messages received on mobile phone
|
|
Brak interwencji: Neither cMM nor Text Messaging
Participants randomized to this arm will receive standard of care with no interventions.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Self-reported adherence on antiretroviral therapy
Ramy czasowe: 12 months post-partum
|
Self-report
|
12 months post-partum
|
|
Adherence on antiretroviral therapy
Ramy czasowe: 12 months post-partum
|
Viral load<100 copies/ml based on medical records
|
12 months post-partum
|
|
Adherence on antiretroviral therapy (infant)
Ramy czasowe: 12 months post-partum
|
Use of ARVs for the infant
|
12 months post-partum
|
|
Retention in care
Ramy czasowe: 12 months post-partum
|
Proportion of women who have an HIV care visit within 90 days at 12 months after the birth
|
12 months post-partum
|
|
Adherence on antiretroviral therapy (dried blood spots)
Ramy czasowe: 12 months post-partum
|
Viral load<100 copies/ml based on dried blood spots
|
12 months post-partum
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Maternal CD4 count change
Ramy czasowe: 6 months after baseline
|
Change in CD4 count baseline to 6 months after baseline
|
6 months after baseline
|
|
Maternal viral load count change
Ramy czasowe: 6 months after baseline
|
Change in viral load from baseline to 6 months after baseline
|
6 months after baseline
|
|
Infant retention in care (feeding method)
Ramy czasowe: 12 and 18 months
|
Infant feeding method
|
12 and 18 months
|
|
Infant retention in care
Ramy czasowe: 12 and 18 months
|
Retention in care through 12 and 18 months
|
12 and 18 months
|
|
Infant retention in care (survival status)
Ramy czasowe: 12 and 18 months
|
Survival status of infant
|
12 and 18 months
|
|
Uptake of intervention services (Number/types of text messages sent)
Ramy czasowe: 3 years
|
Number/types of text messages sent
|
3 years
|
|
Uptake of intervention services (receipt of text messages)
Ramy czasowe: 3 years
|
Receipt of text messages
|
3 years
|
|
Uptake of intervention services (home visits)
Ramy czasowe: 3 years
|
Number of home visits received
|
3 years
|
|
Uptake of intervention services (support groups attended)
Ramy czasowe: 3 years
|
Number of support groups attended.
|
3 years
|
|
Mother-to-Child-Transmission
Ramy czasowe: 6 weeks, 9 months and 18 months
|
Result of infant HIV test at 6 wks, 9,18 months
|
6 weeks, 9 months and 18 months
|
|
Infant testing
Ramy czasowe: 6 weeks, 9 months and 18 months
|
Uptake and date of infant testing
|
6 weeks, 9 months and 18 months
|
|
Infant enrollment in care
Ramy czasowe: 6 weeks
|
Infant enrollment in HIV care
|
6 weeks
|
|
Male partner involvement
Ramy czasowe: 12 months post-partum
|
Composite variable including Y/N response to indicate if male partner attended a health visit with his female partner, encouraged facility delivery, reminded to take HIV medication, reminded to go for HIV care, provided transport money to go to the clinic/dispensary, reminded to give the infant prophylaxis, helped giving the infant prophylaxis medication, collected medication for the woman or infant, encouraged specific infant feeding, and encouraged pediatric HIV testing.
These are assessed in the follow-up questionnaires completed at 12 months post-partum.
|
12 months post-partum
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Lisa Abuogi, MD, MSc, University of Colorado, Denver
Publikacje i pomocne linki
Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.
Publikacje ogólne
- Palmer MJ, Henschke N, Bergman H, Villanueva G, Maayan N, Tamrat T, Mehl GL, Glenton C, Lewin S, Fonhus MS, Free C. Targeted client communication via mobile devices for improving maternal, neonatal, and child health. Cochrane Database Syst Rev. 2020 Jul 14;8(8):CD013679. doi: 10.1002/14651858.CD013679.
- Abuogi LL, Onono M, Odeny TA, Owuor K, Helova A, Hampanda K, Odwar T, Onyango D, McClure LA, Bukusi EA, Turan JM. Effects of behavioural interventions on postpartum retention and adherence among women with HIV on lifelong ART: the results of a cluster randomized trial in Kenya (the MOTIVATE trial). J Int AIDS Soc. 2022 Jan;25(1):e25852. doi: 10.1002/jia2.25852.
- Helova A, Onono M, Abuogi LL, Hampanda K, Owuor K, Odwar T, Krishna S, Odhiambo G, Odeny T, Turan JM. Experiences, perceptions and potential impact of community-based mentor mothers supporting pregnant and postpartum women with HIV in Kenya: a mixed-methods study. J Int AIDS Soc. 2021 Nov;24(11):e25843. doi: 10.1002/jia2.25843.
- Onono M, Odwar T, Wahome S, Helova A, Bukusi EA, Hampanda K, Turan J, Abuogi L. Behavioral Interventions can Mitigate Adverse Pregnancy Outcomes Among Women Conceiving on ART and Those Initiated on ART During Pregnancy: Findings From the MOTIVATE Trial in Southwestern Kenya. J Acquir Immune Defic Syndr. 2021 Jan 1;86(1):46-55. doi: 10.1097/QAI.0000000000002521.
- Wanga I, Helova A, Abuogi LL, Bukusi EA, Nalwa W, Akama E, Odeny TA, Turan JM, Onono M. Acceptability of community-based mentor mothers to support HIV-positive pregnant women on antiretroviral treatment in western Kenya: a qualitative study. BMC Pregnancy Childbirth. 2019 Aug 13;19(1):288. doi: 10.1186/s12884-019-2419-z.
- Odeny TA, Onono M, Owuor K, Helova A, Wanga I, Bukusi EA, Turan JM, Abuogi LL. Maximizing adherence and retention for women living with HIV and their infants in Kenya (MOTIVATE! study): study protocol for a randomized controlled trial. Trials. 2018 Jan 29;19(1):77. doi: 10.1186/s13063-018-2464-3.
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
1 maja 2014
Zakończenie podstawowe (Rzeczywisty)
1 kwietnia 2019
Ukończenie studiów (Rzeczywisty)
1 marca 2021
Daty rejestracji na studia
Pierwszy przesłany
11 marca 2015
Pierwszy przesłany, który spełnia kryteria kontroli jakości
2 lipca 2015
Pierwszy wysłany (Oszacować)
7 lipca 2015
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
26 kwietnia 2021
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
22 kwietnia 2021
Ostatnia weryfikacja
1 kwietnia 2021
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
- Utrzymanie w opiece
- Zdrowie niemowląt
- Związek z opieką
- Transmisja pionowa
- Wczesna diagnoza niemowlęcia
- Transmisja HIV
- Przestrzeganie terapii antyretrowirusowej
- Zapobieganie przenoszeniu się wirusa z matki na dziecko
- Matki Mentorki Społeczności
- Mobile phone text messaging
- Obciążenia CD4/wirusami u matki
- Akceptowalność interwencji
Dodatkowe istotne warunki MeSH
- Zakażenia wirusem RNA
- Choroby wirusowe
- Infekcje
- Infekcje przenoszone przez krew
- Choroby zakaźne
- Choroby przenoszone drogą płciową, wirusowe
- Choroby przenoszone drogą płciową
- Infekcje lentiwirusowe
- Zakażenia Retroviridae
- Zespoły niedoboru odporności
- Choroby układu odpornościowego
- Powolne choroby wirusowe
- Zakażenia wirusem HIV
- Zespół nabytego niedoboru odporności
Inne numery identyfikacyjne badania
- 14-0331
- R01HD080477-01 (Grant/umowa NIH USA)
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Nie
Bada produkt urządzenia regulowany przez amerykańską FDA
Nie
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .